It has been a volatile year for the biotech.

While PFS was not achieved in BioNTech’s cancer vaccine trial, there is still a chance for success with OS.

BioNTech (NasdaqGS:BNTX) and DualityBio reported positive topline results from the DYNASTY-Breast02 Phase 3 trial in HR+/HER2 ...

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, ...

BioNTech recieved a 95 million euro ($110 million) boost from two EU groups that will go toward expanding production of mRNA vaccines in Africa using its modular BioNTainers. (BioNTech) As BioNTech ...

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real ...

Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination. For pharmacists counseling patients this ...

BioNTech had little to say about its pipeline progress on Monday. But it did report COVID vaccine sales which more than doubled analyst consensus. (Photo by Sean Gallup/Getty Images) BioNTech reported ...

BioNTech Impfung is more than just a shot in the arm – it’s one of the most talked?about mRNA vaccines of our time. If you’re still weighing risks, boosters, and alternatives, this deep dive cuts ...

BioNTech (NASDAQ:BNTX) announced Friday two separate agreements worth more than $1B with the National Institutes of Health (NIH) and the University of Pennsylvania to resolve royalty and other claims ...

LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...